Wells Fargo has begun coverage of BIO-TECHNE Corp, providing a price target of $59 whilst also initiating with an 'Overweight' rating. Argus and UBS have adjusted their price targets on the firm to $65 and $70 respectively. Bio-Techne will appear at various investor conferences, presenting its financial performance and innovative biotherapeutic solutions. A bullish case theory continues to be made by analysts noting that despite a dip in Q3 profits, they exceeded estimates. Among new endeavors are an integrated cellular engineering workflow solution, achieved in collaboration with Kytopen, and the expansion of their partnership with Leica Biosystems. New introductions to the team included Dr. Amy E. Herr, appointed to the Board of Directors. Bio-Techne also announced a share repurchase program. Notwithstanding periods of negative funding environments and lower earnings, Bio-Techne remains a compelling inclusion in investment portfolios with a strong growth forecasted, evidenced by top-estimated Q2 and Q3 earnings and revenues. They have also announced the shipment of Leo, their next-generation High-Throughput Simple Western System, which is expected to trigger a rise in stock value. A new customer experience center in DΓΌsseldorf, Germany enhances the firm's global footprint.
Bio-Techne Corp TECH News Analytics from Thu, 22 Jun 2023 07:00:00 GMT to Sat, 31 May 2025 22:12:15 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -2